In conclusion, SHP2 appears to be a promising therapeutic target in combination treatment methods for NSCLC since it plays a critical positive regulatory function in the incidence, metastasis, immune evasion, and drug resistance of lung cancer, regardless of individual RTK/RAS mutational status. Here, PTPN11 is linked to lung cancer.